Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arvinas, Inc. - Common Stock
(NQ:
ARVN
)
7.360
-0.100 (-1.34%)
Delayed Quote
Updated: 2:44 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arvinas, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
October 01, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
September 28, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
September 03, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss
↗
May 12, 2026
Via
Chartmill
Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates
↗
February 24, 2026
Via
Chartmill
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas (ARVN) Q2 2026 Earnings Call Transcript
↗
August 11, 2026
VEPPANU's FDA approval and $50 million Pfizer milestone fuel record net income.
Via
The Motley Fool
Topics
Earnings
Arvinas Q2 Earnings Call Highlights
↗
August 04, 2026
Arvinas (NASDAQ:ARVN) said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval...
Via
MarketBeat
Topics
Earnings
Transcript: Arvinas Q2 2026 Earnings Conference Call
↗
August 04, 2026
Arvinas (NASDAQ:ARVN) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time...
Via
Benzinga
Topics
Earnings
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 04, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
July 28, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
↗
June 05, 2026
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where...
Via
MarketBeat
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 04, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present at Jefferies Global Healthcare Conference
May 29, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026
From
Arvinas Inc.
Via
GlobeNewswire
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
↗
May 13, 2026
Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for...
Via
Benzinga
Arvinas Q1 Earnings Call Highlights
↗
May 12, 2026
Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline...
Via
MarketBeat
Topics
Earnings
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 05, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 01, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days
March 18, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
March 11, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas (ARVN) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
Arvinas (ARVN) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 24, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
February 23, 2026
From
Arvinas Inc.
Via
GlobeNewswire
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 17, 2026
From
Arvinas Inc.
Via
GlobeNewswire
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff
↗
February 12, 2026
Randy Teel has been appointed as President, CEO, as well as a member of the Company’s Board of Directors, effective immediately.
Via
Stocktwits
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
February 12, 2026
From
Arvinas Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
